{"id":392648,"date":"2020-12-03T08:20:26","date_gmt":"2020-12-03T13:20:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392648"},"modified":"2020-12-03T08:20:26","modified_gmt":"2020-12-03T13:20:26","slug":"genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/","title":{"rendered":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8"},"content":{"rendered":"

<\/p>\n

Genprex to Present at the Benzinga Global Small Cap Conference on December 8<\/b><\/p>\n

Presentation to Highlight the Company\u2019s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer<\/i><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–Genprex, Inc.<\/a> (\u201cGenprex\u201d or the \u201cCompany\u201d) (NASDAQ: GNPX<\/a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the Benzinga Global Small Cap Conference taking place virtually December 8-9. Genprex\u2019s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors.\n<\/p>\n

Event: <\/b>Benzinga Global Small Cap Conference
\n
Presentation Date: <\/b>Tuesday, December 8
\n
Presentation Time: <\/b>2:30 p.m. EST
\n
Registration Link: <\/b>https:\/\/bit.ly\/2Jf5TcN<\/a><\/p>\n

\nThe Benzinga Global Small Cap Conference will provide investors with direct access to small caps for insights on their leadership, business fundamentals and plans for expansion. Attending investors will also have the opportunity to meet with management of presenting companies on a one-on-one basis.\n<\/p>\n

About Genprex, Inc.<\/b><\/p>\n

\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex\u2019s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company\u2019s lead product candidate, REQORSA\u2122 (quaratusugene ozeplasmid<\/i>), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca\u2019s Tagrisso\u00ae) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. <\/i><\/p>\n

\nFor more information, please visit the Company\u2019s web site at www.genprex.com<\/a> or follow Genprex on Twitter<\/a>, Facebook<\/a> and LinkedIn<\/a>.\n<\/p>\n

Forward-Looking Statements <\/b><\/p>\n

\nStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex\u2019s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company\u2019s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA\u2122 immunogene therapy drug, alone and in combination with targeted therapies and\/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption \u201cRisk Factors\u201d and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n<\/p>\n

\n\u00a0\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201203005067\/en\/<\/a><\/span><\/p>\n

Genprex, Inc.
\n<\/b>
(877) 774-GNPX (4679)\n<\/p>\n

Investor Relations
\n<\/b>
GNPX Investor Relations
\n
(877) 774-GNPX (4679) ext. #2
\n
investors@genprex.com<\/a><\/p>\n

Media Contact
\n<\/b>
Genprex Media Relations
\n
Kalyn Dabbs
\n
(877) 774-GNPX (4679) ext. #3
\n
media@genprex.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Diabetes Genetics Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Presentation to Highlight the Company\u2019s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the Benzinga Global Small Cap Conference taking place virtually December 8-9. Genprex\u2019s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors. Event: Benzinga Global Small Cap Conference Presentation Date: Tuesday, December 8 Presentation Time: 2:30 … <\/p>\n

Continue reading “Genprex to Present at the Benzinga Global Small Cap Conference on December 8”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392648","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGenprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Presentation to Highlight the Company\u2019s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the Benzinga Global Small Cap Conference taking place virtually December 8-9. Genprex\u2019s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors. Event: Benzinga Global Small Cap Conference Presentation Date: Tuesday, December 8 Presentation Time: 2:30 … Continue reading "Genprex to Present at the Benzinga Global Small Cap Conference on December 8"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T13:20:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genprex to Present at the Benzinga Global Small Cap Conference on December 8\",\"datePublished\":\"2020-12-03T13:20:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/\"},\"wordCount\":791,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/\",\"name\":\"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-03T13:20:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genprex to Present at the Benzinga Global Small Cap Conference on December 8\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/","og_locale":"en_US","og_type":"article","og_title":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk","og_description":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Presentation to Highlight the Company\u2019s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the Benzinga Global Small Cap Conference taking place virtually December 8-9. Genprex\u2019s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors. Event: Benzinga Global Small Cap Conference Presentation Date: Tuesday, December 8 Presentation Time: 2:30 … Continue reading \"Genprex to Present at the Benzinga Global Small Cap Conference on December 8\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T13:20:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8","datePublished":"2020-12-03T13:20:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/"},"wordCount":791,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/","name":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-03T13:20:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201203005067r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-to-present-at-the-benzinga-global-small-cap-conference-on-december-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genprex to Present at the Benzinga Global Small Cap Conference on December 8"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392648"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392648\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}